Fig. 5.

Modelled risk of birth and maternal outcomes among women using dolutegravir and efavirenz

DTG: dolutegravir; EFV: efavirenz; SGA: small for gestational age

Proportion of patients with virologic response with the following definitions: - Plasma HIV RNA <50 copies/ml at week 24 - Rate of strategy discontinuation and treatment changes - Proportion of death - Proportion of patients loss to follow-up24 weeks; Proportion of patients with virologic response with the following definitions: o Plasma HIV RNA <50 copies/ml o Plasma HIV RNA <400 copies/ml24 and 48 weeks; Evolution in HIV RNA and HIV DNA (total and 2 LTR circular) from baseline to week 4848 weeks; Rate of viral resistance mutations in the plasma at the time of virologic failure and in comparison with HIV-RNA mutations at W0At the time of virologic failure; Evolution of CD4 cell counts from baseline to week 4848 weeks; Frequency, type and time to a new AIDS-defining event or deathThrough out the trial; Frequency, type, time to grade 3 or 4 adverse eventThrough out the trial; Rate of success of TB treatment48 weeks; Anti-TB resistance rate48 weeks; Evolution of raltegravir and efavirenz trough concentrationThrough out the trial.